



(51) International Patent Classification:

A61L 27/56 (2006.01) A61F 2/28 (2006.01)
A61F 2/02 (2006.01) A61L 27/54 (2006.01)

(21) International Application Number:

PCT/US2013/043336

(22) International Filing Date:

30 May 2013 (30.05.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/653,019 30 May 2012 (30.05.2012) US

(71) Applicant: NEW YORK UNIVERSITY [US/US]; One
Park Avenue, 6th Floor, New York, NY 10016-5802 (US).(72) Inventors: RICCI, John, L.; 46 Verdun Place,
Middletown, NJ 07748 (US). CLARK, Elizabeth; 215 8th
Street, Apt. #2, Jersey City, NJ 07302 (US). COELHO,
Paulo; 22 N. 6th Street, Apt. 12K, Brooklyn, NY 11249
(US). VAN THOMPSON, Dianne, Rekow; 120 W. 15th
Street, New York, NY 10011 (US). SMAY, James; 3211
S. Saddle Rock Street, Stillwater, OK 74074 (US).(74) Agent: SMITH, David, J.; Klauber & Jackson L.L.C., 25
East Spring Valley Avenue, Suite 160, Maywood, NJ
07607 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: TISSUE REPAIR DEVICES AND SCAFFOLDS



(57) Abstract: The present invention relates to multiphasic, three-dimensionally printed, tissue repair devices or scaffolds useful for promoting bone growth and treating bone fracture, defect or deficiency, methods for making the same and methods for promoting bone growth and treating bone fracture, defect or deficiency using the same. The scaffold has a porous bone ingrowth area containing interconnected struts surrounded by a microporous shell. At the ends of the scaffold, the shell may be extended as a guide flange to stabilize the scaffold between ends of bone. The center of the scaffold may be empty and may serve as a potential marrow space. The porous ingrowth structure may be infiltrated with a soluble filler or carrier, such as, for example calcium sulfate which may be infiltrated with one or more of an antibiotic, a growth factor, a differentiation factors, a cytokine, a drug, or a combination of these agents.

TISSUE REPAIR DEVICES AND SCAFFOLDS

FIELD OF THE INVENTION

[0001] The present invention relates to multiphasic, three-dimensionally printed, tissue repair devices or scaffolds useful for promoting bone growth and treating bone fracture, defect or deficiency, methods for making the same and methods for promoting bone growth and treating bone fracture, defect or deficiency using the same.

BACKGROUND OF THE INVENTION

[0002] Bone and soft tissue defects, in the craniofacial, plastic surgery, and orthopaedic arenas are often filled using autogenous tissue grafts, processed human allograft materials, or alloplastic (synthetic) materials, all of which have deficiencies. Autogenous materials must be harvested from another surgical site, and processed human allografts are expensive, inconsistent, and may pose the risk of disease transmission. Alloplastic materials sometimes perform poorly, are sometimes long lasting or permanent, and can become infected. All of these materials have to be shaped to fit complex sites or are granular in form and must somehow be fixed in place. The search continues for a perfect bone repair material — one that can be custom fabricated to fit complex defects, will stimulate bone repair to fill large bone defects, and will eventually dissolve and/or remodel away leaving only regenerated bone. Some alloplastic materials available for similar uses include those described by Owen *et al.*, *JBMR Part A* 2010, Chen *et al.* *Biomaterials* 2011, Kim *et al.*, *Tiss Eng Part B*, 2010 and Fu *et al.*, *Acta Biomaterialia* 2011.

[0003] Children requiring complex craniofacial repair, like those with alveolar clefts or with Treacher-Collin's syndrome, unlike adults, require fully resorbable materials that can enable bone regeneration in conjunction with craniofacial growth. With bone grafting insufficient to repair these defects, these children require innovation in bone repair technologies. The ideal bone repair scaffold needs to be off-the-shelf and/or custom fabricated to fit closely the lost or missing three dimensional structure. Three dimensional foam scaffold fabrication techniques such as particulate leaching, phase separation/inversion, porogen methods, and spin casting, while controlling overall pore size distribution, do not control individual pore location, pore morphology, and pore

interconnectivity; the latter being a well-documented necessity for promoting exchange of nutrients and metabolites as well as promoting conduction of bone and vascular cells through scaffolds (Lee *et al.*, *J Mater Sci Mater Med* 2010; 21:3195-3205).

[0004] A useful three dimensional printing process, direct write (DW), as detailed by Nadkarni *et al.*, *J Am Ceram Soc* 2006; 89:96-103 is based on the extrusion/deposition of colloidal inks as continuous filaments. DW requires minimal processing aids (i.e., polymers) in the ink for self-supporting filament/struts that will enable printing of the lattice structures required for bone scaffolds. The scaffolds are printed by ink extrusion on the XY plane, “writing” the bottom layer, then moving up in Z height to write additional layers until a three dimensional structure is formed. Post-processing of the printed green bodies requires binder burnout and sintering in a high temperature furnace. The resulting scaffolds are of high resolution and very reproducible.

[0005] Previous work by Simon *et al.*, *J Biomed Mater Res* 2007; 83A: 747-758, consisted of filling rabbit calvarial trephine defects of 11 mm with hydroxyapatite (HA). It is possible to increase scaffold resorption by adding, beta-tricalcium-phosphate (β TCP) to the HA to form a biphasic colloid which has been shown to be osteoconductive and remodelable. Furthermore, calcium sulfate (CS) has been added to fill the space between struts as temporary filler. CS is known to be completely resorbable, osteoconductive, angiogenic, and biocompatible (Thomas *et al.*, *J Biomed Mater Res* 2009; 88B:597-610), and in scaffolds serves to act as a filler that dissolves just ahead of the bone ingrowth front.

[0006] It would be useful to determine how mesopore space and strut patterns determine the morphology of ingrowing bone. Although many studies have been conducted to investigate the relationship between pore size and bone formation, the optimal pore size is unclear with most studies suggesting a range of 100 to 400 μ m (LeGeros, *Clin Orthop Relat Res* 2002; 395:81-98). DW allows the production of controlled mesopore sizes in scaffolds. One previous scaffold design for calvaria defects consisted of an 11mm disk with quadrants comprising different lattice spacings ranging from 250 μ m to 400 μ m. After 8 and 16 weeks *in vivo* the smaller-pore regions produced a different pattern of bone growth and scaffold resorption than the larger-pore regions (Ricci *et al.*, *J Craniofac Surg* 2012; 23:00-00; Ricci *et al.*, “Biological Mechanisms of Calcium Sulfate

Replacement by Bone.” In: Bone Engineering, ed. JE Davies, Em² Inc., Toronto, Ont. Canada, Chapter 30, 332-344, 2000).

[0007] The many clinical situations that require extensive complex bone repair and regeneration continue to represent problems without acceptable solutions. The current clinical treatments are compromises that require elaborate and complex autogenous grafting procedures, or they represent imperfect allogeneic or alloplastic treatment options. In all cases these complex bone repair situations require that materials not made for a specific site are fit as well as possible into the defect. It would be desirable to provide new means for printing three dimensional scaffolds composed of osteoconductive biomaterials that have the potential to be custom-fabricated to repair complex defects.

SUMMARY OF THE INVENTION

[0008] In a first aspect, the present invention provides a tissue repair device or scaffold having a porous bone ingrowth area containing interconnected struts surrounded by a microporous shell. The microporous shell may function to attach but limit soft tissue ingrowth. At the ends of the tissue repair device or scaffold, the shell may be extended as a guide flange to stabilize the tissue repair device or scaffold between ends of bone, across a bone defect, etc. or the tissue repair device or scaffold may be used to repair a defect of a flat bone. The center of the tissue repair device or scaffold may be empty and may serve as a potential marrow space. The porous ingrowth structure may be infiltrated with a soluble filler or carrier, such as, for example calcium sulfate. This soluble filler or carrier, such as, for example calcium sulfate, may be infiltrated with one or more of an antibiotic, a growth factor, a differentiation factor, a cytokine, a drug, or a combination of these agents. The tissue repair device or scaffold may fit between the cortical bone ends of long bone and conduct healing bone, which arises largely from the endosteal and periosteal surfaces or it may be used at or near a bone defect of, for instance, flat bone. The tissue repair device or scaffold may be stabilized using a modified bone plate or bone screws. The tissue repair device or scaffold may be produced by a three dimensional printing procedure and may be formed of, for instance, an osteoconductive ceramic.

[0009] The tissue repair device or scaffold may be a multiphasic, three-dimensionally printed, tissue repair device. The struts may be substantially cylindrical and they may be, for instance, from about 1-1,000, 10-900, 20-800, 30-700, 40-600, 50-500, 60-400, 100-350, 120-300, or about 200-275 μm diameter. In some embodiments, the struts may be about 20-940 μm diameter. In some embodiments the struts are within about 3x, 2x or 1.5x or substantially the same diameter as bone trabeculae. In some embodiments, the struts may be separated longitudinally by a space of up to 100, 200, 300, 400, 500, 600, 700, 800, 900 μm or more, or even 1.0 mm or more. Similarly, the tissue repair device or scaffold may be porous having mesopores that may be present in a size generally less than about 100, 75, 50, 30, 20, 10 or even less than about 5, 4, 3, 2, 1, or even 0.5, 0.4, 0.3, 0.2 or 0.1 μm diameter. The struts may be arranged in a substantially linear arrangement. The tissue repair device or scaffold may be substantially resorbable so that, for instance, after about 8, 10, 12, 16, 18, 20, 24 or so weeks presence *in vivo*, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50% or more of the tissue repair device or scaffold may be resorbed. The tissue repair device or scaffold may be at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or even more porous. Similarly, the tissue repair device or scaffold may be efficient to encourage and provide bone growth such that after about 8 or 16 weeks presence *in vivo*, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50% or more of the tissue repair device or scaffold may be replaced by bone. The tissue repair device or scaffold may promote or form cancellar or cortical bone, within the tissue repair device or scaffold or in the region or area of the tissue repair device or scaffold. The tissue repair device or scaffold may be used to remodel bone or to regionally control the density of bone.

[0010] The tissue repair device or scaffold may feature a gradient of mesopores formed by varying strut spacing in three dimensions (X, Y, and Z). Spacing in the X and Y dimensions may be accomplished using radial or V-shaped patterns with spacing from, for instance, 100-940 μm . Spacing in the Z dimension may be accomplished by stacking multiple layers of the radial struts. The porous ingrowth structure may be infiltrated with a soluble filler or carrier, such as, for example calcium sulfate. In some embodiments, the porous ingrowth structure may be infiltrated with a filler that attracts osteoclasts, such as, for example calcium phosphate mineral and type I collagen protein. In some instances, the printed tissue repair device or scaffold s may be micro/nanoporous on about a 0.1-1 μm pore size level. The pores then may in some instances be infiltrated with solubilized collagen.

[0011] The tissue repair device or scaffold may be effective for promoting bone growth and treating bone fracture, defect or deficiency across a distance of at least 5, 10, 11, 12, 13, 14, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 or more millimeters. Similarly, the tissue repair device or scaffold may be effective for promoting the growth of both cortical or cortical-like bone and trabecular or trabecular-like bone. The bone so grown may be in any suitable proportion, such as, for example 95%, 90%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, 25%, 20%, 10% or so trabecular or trabecular-like bone, or just the opposite, i.e. 95%, 90%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, 25%, 20%, 10% or so cortical or cortical-like bone. The tissue repair device or scaffold may be effective for reducing or shortening the normal repair time across a bone defect by 5, 10, 20, 25, 30, 40, 50, 75, 90% or more. In some instances, the bone defect may be repaired in about half, one third or one quarter of the normally required period of time. In many instances, the larger pore sizes are found near the outer portions of the scaffold and the smaller pore sizes are found near the inner portions of the scaffold. In some instances, the portion of the scaffold forming the inner half of the surface area may have a median pore diameter size or area that is 5, 10, 20, 25, 30, 40, 50, 75, 90% or more smaller than the median pore diameter size or area of the portion of the scaffold forming the outer half of the surface area. In some instances the pore sizes are arranged architecturally in any suitable or desirable configuration so as to customize the type of bone growth, for instance bone density, trabecular-like bone or cortical-like bone, desired. Similarly, in some instances, the tissue repair device or scaffold is formed and shaped to customize the shape of tissue or bone repair desired to optimally span a defect. Further, in some instances, a portion of the tissue repair device or scaffold may be substantially hollow, for instance, 10, 20, 25, 30, 40, 50, 75, 90% or more of the interior portion of the tissue repair device or scaffold may be substantially hollow.

[0012] In a second aspect, the present invention provides a method for promoting bone growth or treating bone fracture, defect or deficiency by providing a tissue repair device or scaffold having a porous bone ingrowth area containing interconnected struts surrounded by a microporous shell. The promoting bone growth or treating bone fracture, defect or deficiency may feature controlling or affecting the density of bone or may feature remodeling bone, for instance, cancellar or cortical bone. In most instances the tissue repair device or scaffold is provided *in vivo* to a region featuring a bone deficiency, fracture or void. The microporous shell may function to

attach but limit soft tissue ingrowth. At the ends of the tissue repair device or scaffold, the shell may be extended as a guide flange to stabilize the tissue repair device or scaffold between ends of bone. The center of the tissue repair device or scaffold may be empty and may serve as a potential marrow space. The porous ingrowth structure may be infiltrated with a soluble filler or carrier, such as, for example calcium sulfate. This soluble filler or carrier, such as, for example calcium sulfate, may be infiltrated with one or more of an antibiotic, a growth factor, a differentiation factors, a cytokine, a drug, or a combination of these agents. The tissue repair device or scaffold may fit between the cortical bone ends of long bone and conduct healing bone, which arises largely from the endosteal and periosteal surfaces. The tissue repair device or scaffold may be stabilized using a modified bone plate or bone screws. The tissue repair device or scaffold may be produced by a three dimensional printing procedure and may be formed of, for instance, an osteoconductive ceramic.

[0013] The tissue repair device or scaffold may be a multiphasic, three-dimensionally printed, tissue repair device. The struts may be substantially cylindrical and they may be, for instance, from about 1-1,000, 10-900, 20-800, 30-700, 40-600, 50-500, 60-400, 100-350, 120-300, or about 200-275 μm diameter. In some embodiments the struts are about 20-940 μm diameter. In some embodiments the struts are within about 3x, 2x or 1.5x or substantially the same diameter as bone trabeculae. In some embodiments, the struts may be separated longitudinally by a space of up to 100, 200, 300, 400, 500, 600, 700, 800, 900 μm or more, or even 1.0 mm or more. Similarly, the tissue repair device or scaffold may be porous having mesopores that may be present in a size generally less than about 100, 75, 50, 30, 20, 10 or even less than about 5, 4, 3, 2, 1, or even 0.5, 0.4, 0.3, 0.2 or 0.1 μm diameter. The struts may be arranged in a substantially linear arrangement. The tissue repair device or scaffold may be substantially resorbable so that, for instance, after about 8, 10, 12, 16, 18, 20, 24 or so weeks presence *in vivo*, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50% or more of the tissue repair device or scaffold may be resorbed. The tissue repair device or scaffold may be at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or even more porous. Similarly, the tissue repair device or scaffold may be efficient to encourage and provide bone growth such that after about 8 or 16 weeks presence *in vivo*, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50% or more of the tissue repair device or scaffold may be replaced by bone.

[0014] The tissue repair device or scaffold may feature a gradient of mesopores formed by varying strut spacing in three dimensions (X, Y, and Z). Spacing in the X and Y dimensions may be accomplished using radial or V-shaped patterns with spacing from, for instance, 100-940 μm . Spacing in the Z dimension may be accomplished by stacking multiple layers of the radial struts. The porous ingrowth structure may be infiltrated with a soluble filler or carrier, such as, for example calcium sulfate. In some embodiments, the porous ingrowth structure may be infiltrated with a filler that attracts osteoclasts, such as, for example calcium phosphate mineral and type I collagen protein. In some instances, the printed tissue repair device or scaffolds may be micro/nanoporous on about a 0.1-1 μm pore size level. The pores then may in some instances be infiltrated with solubilized collagen.

[0015] The tissue repair device or scaffold may be effective for promoting bone growth and treating bone fracture, defect or deficiency across a distance of at least 5, 10, 11, 12, 13, 14, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 or more millimeters. Similarly, the tissue repair device or scaffold may be effective for promoting the growth of both cortical or cortical-like bone and trabecular or trabecular-like bone. The bone so grown may be in any suitable proportion, such as, for example 95%, 90%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, 25%, 20%, 10% or so trabecular or trabecular-like bone, or just the opposite, i.e. 95%, 90%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, 25%, 20%, 10% or so cortical or cortical-like bone. The tissue repair device or scaffold may be effective for reducing or shortening the normal repair time across a bone defect by 5, 10, 20, 25, 30, 40, 50, 75, 90% or more. In some instances, the bone defect may be repaired in about half, one third or one quarter of the normally required period of time. In many instances, the larger pore sizes are found near the outer portions of the scaffold and the smaller pore sizes are found near the inner portions of the scaffold. In some instances, the portion of the scaffold forming the inner half of the surface area may have a median pore diameter size or area that is 5, 10, 20, 25, 30, 40, 50, 75, 90% or more smaller than the median pore diameter size or area of the portion of the scaffold forming the outer half of the surface area. In some instances the pore sizes are arranged architecturally in any suitable or desirable configuration so as to customize the type of bone growth, for instance bone density, trabecular-like bone or cortical-like bone, desired. Similarly, in some instances, the tissue repair device or scaffold is formed and shaped to customize the shape of tissue or bone repair desired to optimally span a defect.

[0016] In a third aspect, the present invention provides a method for producing a tissue repair device or scaffold useful for promoting bone growth or treating bone fracture, defect or deficiency having a porous bone ingrowth area containing interconnected struts surrounded by a microporous shell. The method features (a) providing a microporous shell that may function to attach but limit soft tissue ingrowth, (b) infiltrating a porous ingrowth structure with a soluble filler or carrier, and optionally (c) infiltrating the porous ingrowth structure with one or more of an antibiotic, a growth factor, a differentiation factor, a cytokine, a drug, or a combination of these agents. The soluble filler or carrier may be a filler that attracts osteoclasts, such as, for example calcium phosphate mineral and type I collagen protein. tissue repair device or scaffold useful for promoting bone growth or treating bone fracture, defect or deficiency having a porous bone ingrowth area containing interconnected struts surrounded by a microporous shell may have the features described herein with respect to the first and second aspects of the invention.

BRIEF DESCRIPTION OF THE FIGURES

[0017] Figure 1 is a schematic drawing of a tissue repair device or scaffold design that may be used to regenerate a long bone defect, showing its placement and fixation in the defect. The scaffold has a porous bone ingrowth area (A) containing interconnected 250µm cylindrical struts surrounded by a microporous shell (B) to attach but limit soft tissue ingrowth. At the ends of the scaffold, the shell may be extended as a guide flange (C) to stabilize the construct between the bone ends. The center of the scaffold (D) may be left empty as a potential marrow space. The porous ingrowth structure (outlined with dashed line in upper left drawing) may be infiltrated with a soluble filler/carrier (such as calcium sulfate as an example) that may be infiltrated with one or more of antibiotic, growth factors, differentiation factors, cytokines, drugs, or a combination of these agents. The scaffold may fit between the cortical bone ends (E) of the long bone and conduct healing bone, which arises largely from the endosteal and periosteal surfaces (F). The construct may be stabilized using a modified bone plate (G) and bone screws (H).

[0018] Figure 2 depicts a direct write (DW) printing apparatus based on the extrusion/deposition of colloidal inks as continuous filaments. DW requires minimal processing aids (i.e., polymers) in the ink for self-supporting filament/struts that will enable printing of the lattice structures required for bone scaffolds. The scaffolds are printed by ink extrusion on the XY plane, “writing” the bottom layer, then moving up in Z height to write additional layers until a three dimensional structure is formed. Post-processing of the printed green bodies requires binder burnout and sintering in a high temperature furnace. The resulting scaffolds are of high resolution and very reproducible.

[0019] Figure 3 depicts one previous scaffold design for calvaria defects having an 11 mm disk with quadrants having different lattice spacings ranging from 250 μ m to 400 μ m. After 8 and 16 weeks *in vivo* the smaller-pore regions produced a different pattern of bone growth and scaffold resorption than the larger-pore regions

[0020] Figure 4 depicts two scaffold architectures, (A) small-pore (SP) and (B) large-pore (LP), designed to increase the diversity of pore geometry. Both scaffolds contained a solid cap of layered parallel struts on one surface, which biologically served as a barrier to block soft tissue ingrowth from the scalp, but structurally served as a base for the printing of the scaffold lattice in the Z direction. The scaffold design built upon this base differed between the SP and LP scaffolds, but in general, consisted of a layers of nested concentric circles (CC) alternating with one or more radial (R) layers. Variation of porosity in the Z direction arose from use of 1, 2, or 3 stacks of radial layers, and porosity in the X and Y direction came from the spacing between radial struts in the same layer.

[0021] Figure 5 provides a diagram of a unique mesopore volume formed. A ring of such volumes form the space between CC and R layers in the scaffolds described.

[0022] Figure 6 shows (left) a horizontal slice from SP scaffold after 8 weeks through 1Z height mesopores, with pores formed by concentric circle (CC) and radial (R) struts. All pores but the largest on the outside were evaluated with microCT. As R struts narrowed, bone began to attach to struts. Bone appears discontinuous because it grew upward from between CC rings, as shown in image on (upper-right), a vertical slice of 1Z and 2Z height mesopores at

outer ring from same scaffold. (lower-right), horizontal slice of LP scaffold after 16 weeks. Note the significant formation osteiod (green) where resorbed struts are being replaced with new bone.

[0023] Figure 7 provides the observed 1Z height mesopore percentages from a small pore scaffold having three ring sizes, large, middle and small, after 0, 8 and 16 weeks.

[0024] Figure 8 provides a vertical slice through center and horizontal slices through middle of 3Z mesopores in LP scaffold after 8 weeks.

[0025] Figure 9 provides the observed 2Z height mesopore percentages from a small pore scaffold having three ring sizes, large, middle and small, after 0, 8 and 16 weeks.

[0026] Figure 10 provides the observed 3Z height mesopore percentages from a small pore scaffold having three ring sizes, large, middle and small, after 0, 8 and 16 weeks.

[0027] Figure 11 depicts A) a large pore scaffold; B) a small pore scaffold, before and after removal of outer ring; and C) an enlarged diagram of an outer ring large mesopore. The rectangles correspond to the 3 layers of radial struts between concentric circles and the arrows designate the 4 open walls of the mesopore.

[0028] Figure 12 provides a microCT scan of a large pore scaffold after 16 weeks. The scaffold is seen digitally sectioned both vertically through the center and horizontally between superficial and deep mesopores. The scaffold and cap appear darker, and the surrounding hard tissue appears in lighter shade.

[0029] Figure 13 shows horizontal slices from a scaffold through mesopores.

[0030] Figure 14 provides a vertical slice through the center and horizontal slices through middle of 3Z mesopores in a scaffold.

[0031] Figure 15 provides slices through a scaffold demonstrating the growth of both cortical and trabecular bone.

[0032] Figure 16 depicts a scaffold having a four quadrant mesopore design having mesopores of differing sizes in distinct quadrants.

[0033] Figure 17 depicts two scaffold architectures, (A) small-pore (SP) and (B) large-pore (LP), designed to increase the diversity of pore geometry. The small-pore design has pore dimensions of from 0-410 μm , and the large-pore design has pore dimensions of from 250-940 μm .

[0034] Figure 18 graphically depicts the fraction of scaffold loss (remodeling) versus scaffold volume at 8 weeks after implant clearly demonstrating bone growth.

[0035] Figure 19 graphically depicts bone as a fraction of available space versus scaffold volume at 8 weeks after implant clearly demonstrating bone growth.

[0036] Figure 20 graphically depicts the fraction of scaffold, space or soft tissue, and bone volumes present at 0 and 8 weeks after implant for a large pore (left) and a small pore (right) scaffold. The large pore scaffold has pore sizes in the 428-636 μm range with a z axis of 616 μm . The small pore scaffold has pore sizes in the 25-188 μm range with a z axis of 410 μm .

[0037] Figure 21 provides (a) a diagram of a longitudinal section of a bone defect having a scaffold placed therein (top); (b) a diagram of a the end view of a printed scaffold (bottom left); (c) a side view of a bone defect suitable for a tissue repair device or scaffold (bottom center); and (d) a top view of a bone defect suitable for a tissue repair device or scaffold (bottom right).

DETAILED DESCRIPTION OF THE INVENTION

[0038] Multiphasic, three-dimensionally printed, tissue repair device (M3DRD) scaffolds may be used to replace current bone grafting techniques and bone graft substitutes, all of which have serious drawbacks and cannot be produced in the complex designs and shapes necessary for repair

of complex bone defects. M3DRDs can be custom produced for complex grafting applications for craniofacial and orthopaedic bone repair.

[0039] The multiphasic, three-dimensionally printed, tissue repair device (M3DRD) is a device beginning with at least one component, and possibly comprising three or more components (Figure 1). The main components are (1) the scaffold, (2) the temporary filler/carrier material, and (3) a bioactive molecule/drug contained in the filler/carrier.

The Scaffold

[0040] The core of the M3DRD is a three-dimensional scaffold that may be produced using a 3-D printing technique referred to as robotic deposition or direct write (DW) technology (*See*, Figure 2). This technique uses a computer controlled printing process and colloidal inks to form three-dimensional structures. These structures can form on the self components or can be custom formed for filling individual bone defects from tomographic data (X-ray, sonographic or MRI).

[0041] Ink fabrication and the printing system itself are described in more detail in other references, but basically the system uses water-based rheologically controlled inks that become solid as they leave the print nozzle. These inks consist of finely controlled ceramic particles in a water-based slurry containing organic chemicals that control the handling characteristics of the colloidal ink. This allows 3-D lattice-like structures to be printed, in layers, without or with minimal sag of unsupported structural elements.

[0042] Using this system, the elements of the first layer may be printed by forcing the ink through a small (~50-400 μ m diameter) nozzle onto a support plate, using the x and y coordinate control system of an x-y-z control gantry system. Then the z control system is used to move the nozzle up slightly less than 1 nozzle diameter. Then the next layer is printed over the first layer. This is continued layer-by-layer until the entire 3-D structure is finished.

[0043] The entire structure may be printed in an oil bath to prevent drying. The system may have 3 nozzles and ink reservoirs so that up to three materials can be used to print a single structure. Fugitive inks, inks consisting entirely of material that burn off during firing, may also be used as

part of the printing process. These can be used to print support structures for complex parts requiring temporary supports.

[0044] The resulting structures are then removed from the oil bath, dried, and fired in a programmable furnace to produce the final ceramic structure. Firing is currently done at approximately 1100°C for about four hours, which substantially burns off the organic components, sintering the ceramic particles together into a solid structure. This may cause a small amount of predictable shrinkage that can be calculated into the printing process to produce precise and predictable structures.

[0045] The print nozzles may be routinely cylindrical producing cylindrical rod printed structures. However, nozzles may be made that are shaped to produce non-cylindrical structures or structures with surface striations of sizes designed to control cell migration, growth, and differentiation based on our earlier surface modification patents. (*See*, U.S. Patent 6,419,491)

Composition

[0046] Calcium phosphate base scaffold were made from inks based upon permanent, remodelable (through bone remodeling processes), or soluble materials, or some combination of these. Some promising materials at this time are hydroxyapatite (HA) ceramics, tricalcium phosphate ceramics (TCP), and biphasic ceramics (HA/TCP) having a combination of the two materials. The HA materials produce permanent or very long-lasting scaffolds (depending on firing temperatures), the HA/TCP combinations may be varied with high HA percentages producing long-lasting scaffolds, and ~99%TCP/1%HA scaffolds have been used to produce scaffolds that have been shown to remodel significantly through osteoclastic activity. Some such scaffolds contain approximately 3 mm thick, 11 mm diameter porous disks, with varying pore structures in different regions of the disk, and about a 0.5 mm thick solid cap structure of about 12 mm diameter. These have been inserted into 11 mm diameter trephine holes in rabbit parietal (skull) bones to test the bone and soft tissue response. It was demonstrated that these scaffolds can effectively be produced to have combinations of solid shell components to restrict fibrous tissue infiltration, and internal lattice structures with 270 µm diameter elements (this diameter can be varied using nozzle size) and pores (mesopores) ranging in size from less than 100 µm to 1000 µm in largest dimension. These constructs, with pores and strut sizes above the micron scale and below millimeter scale are

referred to as mesostructures. The lattice structures, because of the HA and TCP composition, promote osteoconduction of new bone into the scaffolds. By adding small organic particles to the inks, microporous (on a submicron to ~20 μm pore size) scaffold components can also be produced. These can be designed to attach fibrous connective tissue. Using these combinations of solid layers, various size open-weave mesopore lattices, microstructured lattice elements, and microporous lattice elements, complex structures can be designed and fabricated to conduct the ingrowth and formation of bone, marrow tissue, fibrous tissue, and blood vessels. An example of a scaffold for long bone regeneration is shown in Figure 1. Since the DW system can print more than one material in a scaffold, it is feasible to print scaffolds with permanent HA components as well as remodelable TCP elements. This may be applicable in orthopaedic applications where long-term strength of the scaffold is necessary.

The scaffold filler/carrier material and bioactive factors

[0047] This filler/carrier component has a cement, polymer, or organic/natural hydrogel-based material that may be used to infiltrate the scaffold to produce a solid or nearly solid (if the filler is microporous) composite structure. This filler/carrier material may be soluble at some known or controlled rate, provide the scaffold with greater initial mechanical strength and stability, and then dissolve to allow and/or stimulate bone or soft tissue ingrowth (depending on the application and design). The filler/carrier may dissolve from the outside of the scaffold inward to its center, allowing the composite to become porous, as the scaffold component is exposed, and as tissue and blood vessels grow in from the surrounding tissue. This component may also protect the internal portion of the scaffold from the formation of a blood clot that may normally form there during early healing. This blood clot may become infected in oral and craniofacial sites where these sites are often non-sterile, or may become a granulation/fibrous tissue or necrotic either of which can impede bone ingrowth. The filler/carrier material may inherently stimulate tissue formation, or it may contain incorporated drugs, growth factors, cytokines, or antibiotics.

[0048] Some exemplary filler/carrier materials are calcium sulfate (plaster of paris), timed release calcium sulfate (a slow-dissolution version of calcium sulfate), and chitosan, a derivative of chitin, a biologically-derived polysaccharide, that can be used as a coating or hydrogel filler. Other materials, such as resorbable polymers like pol(L-lactic acid) (PLLA), may be used as filler/carrier materials, but alternatively these may be used as a coating material for the scaffold rather than

filler. As such, they can still strengthen the scaffold and act as release materials, but may not be utilized to fill the scaffold and make it a solid structure.

[0049] Calcium sulfate was used as a filler and as a drug carrier material, where it was found to enhance mechanical properties of the structures, release biologically active agents in a predictable way, and not interfere with bone formation. Bioactive molecules investigated using this carrier include recombinant Platelet derived Growth Factor (PDGF) and Bone Morphogenetic Protein (BMP).

Using scaffold mesostructure to control scaffold mechanical characteristics, bone characteristics, and scaffold remodeling

[0050] It is possible to design and produce scaffolds with mechanical properties suitable for use in craniofacial bone repair, and which, with some external support, are appropriate for orthopaedic repair. Scaffold mesostructure may also be used to control the structural characteristics and density of bone that is conducted into the scaffolds. Using a rabbit 11 mm diameter trephine defect as a model, three different design scaffolds were produced to fill the defects and examine bone regeneration. All scaffolds were produced of the same material, 99% TCP 1%HA ceramic, and were made of the same sized printed struts that were 270µm in diameter. All scaffolds were also filled with medical grade calcium sulfate, and started as solid structures. Mesostructure was varied using strut spacing in the layers of the scaffold (x and y directions) and by stacking struts in the z direction. One type of scaffold that contained three strut spacings that produced open pores that were referred to (in the x and y directions) as 250 x 250µm, 250 x 400µm, and 400 x 400µm size pores was produced (these dimensions are approximate). “Z” spacing was slightly less than one strut in height, or 230µm. As measured by microcomputed tomography, these three zones had scaffold volume percentages of 46, 56, and 70%.

[0051] Two scaffolds were produced that had continuously variable porosity produced using radial struts alternating with concentric rings of different spacings. One scaffold had layers of 1 z and 2 z spacing and ring-shaped regions with scaffold volumes ranging from 55 to 94%. The other scaffold had 3 z spacing and regions ranging from 41 to 56% volume. Thus, a range of scaffold volumes were tested ranging from 41 to 94% scaffold. In all scaffolds, bone was capable of consistently growing to the center of the defect (across 5.5mm distance) by 8 weeks.

[0052] This extent of consistent bone infiltration has not been observed in other osteoconductive scaffolds, and is due to the size and organization of the scaffold elements in the scaffolds. By using many small struts, in the size range of bone trabeculae, to conduct ingrowth, and by organizing them in ways that conduct bone in straight lines across the defects, it is possible to optimize the process of osteoconduction. This process, referred to as “directed osteoconduction” is novel to this type of scaffold. In scaffolds with random pore organization, the process of directed osteoconduction is not observed, and there consistent growth across large defects takes longer to occur. With the structures described herein, bone volumes at 8 and 16 weeks ranged from 9 to 40% (8 weeks) and 10 to 56% (16 weeks). Bone volume was inversely related to scaffold volume. More open (lower scaffold volume) scaffolds showed more bone ingrowth, and bone increased over time. Scaffold remodeling ranged from 5% to 56%, with more remodeling being observed in more open scaffolds at later time periods. Higher volume scaffolds (with smaller pores) produced more compact, lamellar bone, with the combination of scaffold and bone showing very little soft tissue and resembling a cortex-like structure. In contrast, lower volume scaffolds (with larger pores) produced more porous, disorganized bone, with the combination of bone and scaffold resembling cancellous bone. The type of bone adjacent to the scaffold (cortical or cancellous) at least partially influenced the bone growing in the adjacent scaffold.

Features of M3DRD scaffolds

[0053] In all, this data shows that osteoconductive scaffolds with designed mesostructures can be made with mechanical properties suitable for a wide range of bone repair applications. These scaffolds can be used to regenerate bone across significant distances without the need for bone cell or stem cell augmentation. The observed rate of osteoconduction across large defects is due to “directed osteoconduction” based on the use of many small struts, in the size range of bone trabeculae, that are organized in straight arrays to conduct bone efficiently across large distances.

[0054] The scaffolds can also be used to control resulting bone density, structure, and scaffold remodeling rates. The M3DRD scaffolds can be designed so that they regenerate bone that microstructurally approximates or matches adjacent bone. That is, where cancellous bone is needed, it is possible to regenerate cancellous structure, and where cortical bone is needed, it is possible to regenerate that form as well. Additional features like solid cap layers may successfully

prevent soft tissue ingrowth. The CS filler may temporarily enhance structural mechanical properties and not impede bone formation and prevent fibrous tissue ingrowth and infiltration by infection and allow angiogenesis to proceed.

[0055] The CS can also be used for controlled release of bioactive molecules. Use of the DW printing system allows custom design and printing of complex mesostructures with micron scale accuracy. This allows both off-the-shelf printed structures as well as custom printed M3DRD scaffolds for repair of complex defects in patients, based on MRI or CT data. This technology has widespread application in the craniofacial and orthopaedic bone repair/replacement fields.

Exemplary tissue repair device or scaffold

[0056] Bone defects are currently filled by complex autogenous grafting procedures; or imperfect allogeneic or alloplastic treatments not designed for a specific site. Direct Write (DW) fabrication allows us to print 3-D scaffolds composed of osteoconductive biomaterials, complex multicomponent biphasic (COMBI) calcium phosphate scaffolds that have the potential to be custom-fabricated to repair complex bone defects. Current literature still debates optimum and threshold pore requirements for bone regeneration. We tested scaffolds in a critical-sized (unable to close on its own) *in vivo* model to study effects on bone density, extent of ingrowth, and bone/scaffold remodeling.

[0057] Scaffolds were designed with variable mesopore spacing in all (X, Y, and Z) planes. To vary pore sizes, two scaffold designs of layers of concentric circles, alternating with radial struts of 1, 2, or 3 overlapping layers in z height, were fabricated by DW from 15:85 HAP/ β -TCP and sintered at 1100°C. A calcium sulfate temporary filler prevented soft tissue invasion and/or infection. Scaffolds were embedded *in vivo* in trephine defects. After 8-16 weeks, analysis of bone ingrowth and scaffold and bone remodeling was quantified by MicroCT (Scanco Medical) and scaffolds were embedded in polymethylmethacrylate (PMMA) then evaluated histologically with light microscope.

[0058] Scaffold volume was designed to vary by ring section. Bone volume was higher in the more open, less scaffold-dense areas. Pores ranged from around 100 to 940 microns. Bone grew

into all varied height layers, but appeared to take longer to get through largest pore sizes. Pores larger than 500 microns still filled with bone well contrary to previous literature findings.

[0059] Particular scaffolds used demonstrated that three dimensional printed calcium phosphate scaffolds are capable of growing bone across at least 11 mm voids in 8 weeks. Bone can grow into pores as large as 940 μm and as small as 20 μm . Bone morphology can be trabecular-like or cortical-like depending on scaffold design. The scaffolds may be designed with regionally different biological and mechanical properties for a wide range of clinical applications.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

EXAMPLE 1

Materials and Methods

[0060] Two scaffold architectures, small-pore (SP) and large-pore (LP), were designed to increase the diversity of pore geometry. Both scaffolds contained a solid cap of layered parallel struts on one surface, which biologically served as a barrier to block soft tissue ingrowth from the scalp, but structurally served as a base for the printing of the scaffold lattice in the Z direction. The scaffold design built upon this base differed between the SP and LP scaffolds, but in general, consisted of a layers of nested concentric circles (CC) alternating with one or more radial (R) layers. Variation of porosity in the Z direction arose from use of 1, 2, or 3 stacks of radial layers, and porosity in the X and Y direction came from the spacing between radial struts in the same layer. The specific designs of SP and LP scaffolds are diagrammed in Figures 4 and 5.

[0061] Scaffolds printed with ink of 15:85 HA/ β -TCP and fired at 1100°C. Scaffolds were then scanned at medium resolution in microCT (Scanco Medical) to evaluate the volume of struts and mesopores before implantation. Scaffolds were then filled with CS and a 1mm ring of scaffold above the cap was removed with a dental drill to open the blocked radial struts in the perimeter. This left a diameter of 11mm.

Surgical Procedure

[0062] Surgery was performed on 8 adult New Zealand White Rabbits following an Institutional Animal Care and Use Committee (IACUC) approved protocol. A 3.0cm midsagittal incision was made through the skin and soft tissue of the dorsum of the head. Bilateral 11.0 mm diameter trephine defects were made immediately posterior to the coronal suture in the parietal bone, without dural involvement.

[0063] After placement of LP and SP scaffolds in right and left defects, respectively, the soft tissue and skin was closed with 4-0 resorbable sutures. Wounds were cleaned with sterile saline and treated with triple antibiotic ointment. No signs of infection, pain, or other complications resulted. 7 animals were euthanized after 8 weeks and 1 animal after 16 weeks.

Sample Analysis

[0064] Resected implants with surrounding tissue were fixed in 70% ethanol and scanned in microCT at medium resolution. Volumes of interest within each sample were the volumes occupied by each ring of unique mesopore volumes (see Figures 4 and 5). The outer volumetric ring of all samples was not measured because it was found that bone filled this space in an unfilled defect (Sohn *et al.*, *J Periodontal Implant Sci* 2010; 40:180-187). Each SP scaffold contained 6 uniquely sized mesopore rings: 3 concentric ring volumes for each 1Z and 2Z location. Each LP scaffold contained 2 uniquely sized mesopore volumes, formed by the concentric rings within the 3Z locations. For each unique ring of mesopores, volume percentages for bone, scaffold, and soft tissue/space were obtained by setting two thresholds: scaffold (S) and scaffold+bone (SB). Percentage of bone ingrowth was measured by subtracting S from SB, and percentage of soft tissue/space was measured by subtracting SB from 100%. Scaffold resorption was measured by subtracting S from scaffold volumes measured before implantation. (See, Figures 7, 9, 10).

[0065] Samples were then embedded in methylmethacrylate for histology, and 80µm thick slices were prepared at specific points through the R layers of each sample. For each SP scaffold, horizontal slices (parallel to cap) were taken through the 1Z and the two 2Z mesopore sections. For each LP scaffold, horizontal slices were taken through the two 3Z mesopores. Furthermore, a vertical slice (perpendicular to cap) was taken through the center of all scaffolds. All slices were stained and digitally photographed. (See, Figures 6, 8)

[0066] Other samples were examined using scanning electron microscopy (SEM) (Hitachi) with backscattered electron imaging (BEI) and EDAX evaluation to analyze mineral composition. Based on earlier studies (Simon *et al.*, *J Biomed Mater Res* 2008; 85A:371-377), the sample size used here had statistical power to determine a 15-20% difference between groups with a *p* value of less than 0.05.

Results

[0067] Micro CT and histological analysis revealed bone ingrowth into mesopores of all dimensions. Higher percentages of bone were found in the larger pores at the perimeter of both SP and LP scaffolds. In general, more scaffold strut resorption occurred in areas with higher bone ingrowth. Though in the SP scaffold, at the inner ring of 2Z mesopores, which contained smaller volumes with less bone growth, strut resorption was higher. Histological results of these more closed areas showed bone which grew directly on the struts, rather than between them. In the 1Z mesopores, bone did not appear to grow inward from the perimeter, but rather grew from between CC rings from 2Z mesopores.

[0068] The CS filler appeared to resorb as bone filled in, however histology images showed remaining islands of precipitate, which SEM, BEI, and EDAX showed to be calcium phosphate (CaP). This has been reported in other studies. In most animals, the CaP appeared to conduct bone growth and integrate with bone formation, but in other animals, areas of highly dense CaP precipitation appeared to block bone formation.

Discussion

[0069] Variable mesopore scaffolds made of TCP and filled with CS allow designing scaffolds to regrow bone structure similar to cortical and trabecular bone. It is important to note that analysis of histology is still ongoing. The large accumulation of CaP precipitate is believed to be a result of a saturated solution Ca^{2+} and PO_4^{3-} which accumulated in the tight mesopore spaces as CaS resorbed. The acidic nature of dissolving CaS may also have increased the release of Ca^{2+} and PO_4^{3-} from the TCP of surrounding scaffold struts.

[0070] MicroCT results after 8 weeks show a gradient of percentages of scaffold+bone (SB) of roughly 68-99% and a gradient of scaffold resorption of 4-14%. Most surprisingly, the mesopore

volumes which maximized scaffold resorption near 14% were near opposite ends of the volume spectrum, the larger being 428-636 μ m x 616 μ m and the smaller 188-253 μ m x 410 μ m. Of these two volumes, the larger gave an SB of 67.56% (40.19%B + 27.37%S) and the smaller an SB of 92.93% (27.25%B + 65.68%S), closely resembling the bone percentages of trabecular and cortical bone, respectively. Although the smaller mesopores conducted less bone, they appeared to cause equally high strut resorption because of how they directed the bone front, with associated osteoclasts, directly along the strut surfaces.

[0071] These data demonstrate the relationship between bone ingrowth/remodeling and pore volume. Future studies will test scaffold designs using pore dimensions designed to regenerate microanatomically correct bone. Control of resorption of these scaffolds will allow their use for facial reconstruction of children with craniofacial deformities.

EXAMPLE 2

Background

[0072] Repair of bone lost to trauma, disease, or birth defect currently requires regeneration of large volumes of structurally complex bone. This typically involves autogenous bone grafting, which is an imperfect process due to procurement morbidity, longer operative time, and limited bone availability. Furthermore, current alternatives to autogenous grafts each contain their own unique downsides. Processed human cadaver bone and xenogenic bone, while sparing the need for a secondary surgical site, risk transmitting infection and triggering autoimmune reactions. Additionally, treatment with alloplastic materials, such as calcium phosphate ceramics and cements, though osteoconductive and/or osteoinductive, are mechanically unstable in large defects and incapable of complete osteolytic resorption. Thus, research teams have been working to design calcium phosphate scaffolds that are both mechanically stable and resorbable.

[0073] One such scaffold material, a biphasic composite of hydroxyapatite (HA) and beta-tricalcium phosphate (β -TCP), is commonly known as biphasic calcium phosphate (BCP). The development of BCP as a bone graft material was based on the concept of the preferential dissolution of β -TCP over HA.

[0074] Bone ingrowth into BCP scaffolds mimics primary bone formation into a defect or wound site, which occurs as directional growth of new immature trabeculae, from the endosteal or periosteal layers of damaged cortical and cancellous bone into the defect. This only occurs, however, if the scaffold has appropriate surface chemistry and microtexture, for osteoconduction, and can only occur in a structurally controlled manner with the appropriately selected scaffold mesostructure (50-1000 range).

[0075] The use of solid freeform fabrication such as Direct Write (DW) fabrication allows us to print 3-D scaffolds composed of osteoconductive biomaterials that have the potential to be custom-fabricated to repair large complex defects. Complex multicomponent biphasic (COMBI) scaffolds have been produced by DW and studied in vitro. Current literature still debates optimum and threshold pore sizes required for bone ingrowth.

[0076] A COMBI scaffold has been designed which contains a graded mesopore spacing in all (X, Y, and Z) planes. The present study will test this design in vivo in a bilateral critical-sized (unable to close on its own) rabbit calvarial defect model to demonstrate how pore size affects bone density, extent of ingrowth, and bone/scaffold remodeling.

Methods

[0077] Two uniquely structured scaffolds, one with larger pore sizes and one with smaller pore sizes, were designed by overlaying, in the Z plane, layers of concentric circles with 1, 2, or 3 layers of radially oriented struts. All scaffolds were designed with a solid cap on one end to prevent soft tissue invasion and an open antrum on the other as a result of inner circular layers. Such scaffolds were fabricated by DW, printed as COMBI structures from 15:85 HAP/ β -TCP, and then sintered at 1100°C. Surgical grade calcium sulfate was used as a temporary filler to prevent soft tissue invasion and /or infection through the mesopores. The outer ring of all scaffolds was removed with a dental drill to open the outer barrier created by the layering of radial strut during the printing process.

[0078] In 8 New Zealand white rabbits, one large and one small-pore scaffold were embedded bilaterally by the rabbit trephine model. In 7 rabbits, 14 scaffolds were removed after 8 weeks for

analysis. The 2 scaffolds were removed from the remaining rabbit after 16 weeks for analysis. The amount of bone ingrowth and scaffold remodeling as fractions of mesopore volume were quantified by MicroCT(Scanco Medical). Samples were dehydrated with alcohol, cleared with methylsalicylate, and then embedded in polymethylmethacrylate (PMMA). Large pore scaffolds were sectioned into one central vertical slice and two horizontal slices through the 3z height mesopores.. Small pore scaffolds were sectioned in one central vertical slice, two horizontal slices through the 2z mesopores, and one horizontal slice through the 1z mesopore. Sections were evaluated using scanning electron microscopy (SEM; S-3500 N, Hitachi Instruments) and histology with light microscope (Aperio).

Results

[0079] Scaffold volume was designed to vary by ring section. Bone volume was higher in the more open, less scaffold-dense areas. Pores ranged from around 100 to 940 microns. Bone grew into all varied height layers, but appeared to take longer to get through largest pore sizes. Pores larger than 500 microns still filled with bone well contrary to previous literature reports. Scaffold volume was designed to vary by ring section. Bone volume was higher in the more open, less scaffold-dense areas. Pores ranged from around 100 to 940 microns. Bone grew into all varied height layers, but appeared to take longer to get through largest pore sizes. Pores larger than 500 microns still filled with bone well contrary to previous literature findings.

[0080] Table 1 relates the ratio of scaffold volume to total volume in A) 8 large pore scaffolds after printing, B) the superficial mesopores of 3 large pore scaffolds after 8 weeks, and C) the deep mesopores of 3 large pore scaffolds after 8 weeks.

A

Totoal mesopores	Outer Ring	Middle Ring	Inner Ring
After			
Printing			
Mean	33.67	40.83	55.78
SD	1.83	1.55	0.72

B

Superficial mesopore	Outer Ring	Middle Ring	Inner Ring
After 8	17.07	24.09	43.47
Weeks	16.31	28.63	45.85
	9.55	32.16	55.63
Mean	14.31	28.29	48.32
SD	4.14	4.05	6.44

C

Deep mesopore	Outer Ring	Middle Ring	Inner Ring
After 8	11.74	24.13	38.96
Weeks	16.3	22.36	47.87
	13.82	31.22	52.13
Mean	13.95	25.90	46.32
SD	2.28	4.69	6.72

[0081] While the present invention has been set forth in terms of a specific embodiment or embodiments, it will be understood that the present scaffolds and methods herein disclosed may be modified or altered by those skilled in the art to other configurations. Accordingly, the invention is to be broadly construed and limited only by the scope and spirit of the claims appended hereto.

CLAIMS

What is claimed is:

1. A tissue repair device or scaffold having a porous bone ingrowth structure containing interconnected struts surrounded by a microporous shell.
2. A tissue repair device or scaffold according to claim 1 wherein the microporous shell is extended as a guide to stabilize the tissue repair device or scaffold between one or more ends of bone.
3. The tissue repair device or scaffold according to claim 1 having a center defined by an empty space.
4. The tissue repair device or scaffold according to claim 1 wherein the porous ingrowth structure is infiltrated with a soluble filler or carrier.
5. The tissue repair device or scaffold according to claim 4 wherein the soluble filler or carrier is calcium sulfate.
6. The tissue repair device or scaffold according to claim 4 wherein the soluble filler or carrier is infiltrated with one or more of an antibiotic, a growth factor, a differentiation factor, a cytokine, a drug, or a combination thereof.
7. The tissue repair device or scaffold according to claim 1 wherein the struts are from about 100-350 μm diameter.
8. The tissue repair device or scaffold according to claim 1 wherein the struts are within about 2x or substantially the same diameter as bone trabeculae.

9. The tissue repair device or scaffold according to claim 1 wherein one or more struts are separated longitudinally by a space of at least 500 μm .
10. The tissue repair device or scaffold according to claim 1 being porous and comprising mesopores present in a size generally more than about 20 μm diameter.
11. The tissue repair device or scaffold according to claim 1 wherein the struts are arranged in a substantially linear arrangement.
12. The tissue repair device or scaffold according to claim 1 being resorbable so that after about 8 weeks presence *in vivo*, at least about 25% of the tissue repair device or scaffold is resorbed.
13. The tissue repair device or scaffold according to claim 1 being at least about 50% porous.
14. The tissue repair device or scaffold according to claim 1 being operable to encourage and provide bone growth such that after about 8 weeks presence *in vivo*, at least about 25% of the tissue repair device or scaffold is replaced by bone.
15. The tissue repair device or scaffold according to claim 1 comprising micropores or nanopores having a diameter of about 0.1-1 μm .
16. The tissue repair device or scaffold according to claim 15 wherein one or more micropores or nanopores are infiltrated with solubilized collagen.
17. The tissue repair device or scaffold according to claim 1 produced by a three dimensional printing method.
18. A method for promoting bone growth or treating bone fracture, defect or deficiency comprising providing a tissue repair device or scaffold having a porous bone ingrowth structure containing

interconnected struts surrounded by a microporous shell according to claim 1 *in vivo* to a region featuring a bone deficiency, fracture or void.

19. A method for producing a tissue repair device or scaffold useful for promoting bone growth or treating bone fracture, defect or deficiency having a porous bone ingrowth region containing interconnected struts surrounded by a microporous shell, comprising:

- (a) providing microporous shell that may function to attach but limit soft tissue ingrowth, and
- (b) infiltrating the porous ingrowth structure with a soluble filler or carrier.

20. A method according to claim 19 further comprising (c) infiltrating the porous ingrowth structure with one or more of an antibiotic, a growth factor, a differentiation factors, a cytokine, a drug, or a combination of these agents.

Figure 1




Figure 2

2/21




Figure 3

3/21




Figure 4

4/21



Small Pore Scaffold:**Large Pore Scaffold**

Figure 5

5/21




Figure 6

6/21






Figure 7

7/21



**1Z Height Mesopore Percentages from Small Pore (SP) Scaffold**

Figure 8

8/21



Figure 9

9/21




Figure 10

10/21




Figure 11

11/21




Figure 12

12/21




Figure 13

13/21




Figure 14

14/21




Figure 15

15/21




Figure 16

16/21




Figure 17

17/21




Figure 18

18/21




Figure 19

19/21




Figure 20

20/21





Figure 21

21/21



A. CLASSIFICATION OF SUBJECT MATTER**A61L 27/56(2006.01)i, A61F 2/02(2006.01)i, A61F 2/28(2006.01)i, A61L 27/54(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61L 27/56; A61F 2/28; A61F 2/02; B29C 41/02; A61K 38/18; B29C 35/08; A61L 27/54

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & keywords: tissue repair, scaffold, porous bone ingrowth structure, interconnected struts, microporous shell, three dimensional printing

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHERWOOD et al., `A three-dimensional osteochondral composite scaffold for articular cartilage repair` Biomaterials, Vol.23, pp.4739-4751 (December 2002) See the whole document.	1-17
A	US 2008-0206297 A1 (ROEDER et al.) 28 August 2008 See abstract; claim 1; figures 1A,1B.	1-17
A	US 2011-0313538 A1 (OH et al.) 22 December 2011 See abstract; claim 1; figures 10,11.	1-17
A	US 2003-0006534 A1 (TABOAS et al.) 9 January 2003 See abstract; claims 1-5; figure 3.	1-17



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 October 2013 (15.10.2013)

Date of mailing of the international search report

16 October 2013 (16.10.2013)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
189 Cheongsa-ro, Seo-gu, Daejeon Metropolitan City,
302-701, Republic of Korea

Facsimile No. +82-42-472-7140

Authorized officer

KIM Seung Beom

Telephone No. +82-42-481-3371



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2013/043336

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18-20
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 18-20 are directed to a treatment method of the human body by surgery and thus relate to a subject matter which this International Searching Authority is not required, under Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2013/043336

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2008-0206297 A1	28/08/2008	WO 2008-106625 A2 WO 2008-106625 A3	04/09/2008 30/12/2009
US 2011-0313538 A1	22/12/2011	CA 2695946 A1 EP 2192876 A2 WO 2009-021209 A2 WO 2009-021209 A3	12/02/2009 09/06/2010 12/02/2009 23/04/2009
US 2003-0006534 A1	09/01/2003	US 7087200 B2 WO 03-000480 A1	08/08/2006 03/01/2003